Unanswered questions in acute myeloid leukaemia

Lancet Oncology

Volumn 5, Issue 7, 2004, Pages 443-450

  Ferrara, Felicetto ^a,b  

^a CARDARELLI HOSPITAL   (Italy)

^b NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CALICHEAMICIN; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; IMATINIB; IMMUNOSUPPRESSIVE AGENT; MITOXANTRONE; PROTEIN BCL 2; RAS PROTEIN; RETINOID DERIVATIVE; TIOGUANINE; TRANSCRIPTION FACTOR RUNX1; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; CANCER REGRESSION; CANCER SURVIVAL; CHROMOSOME 16; CHROMOSOME ANALYSIS; CLINICAL FEATURE; CLINICAL TRIAL; ELDERLY CARE; GENE MUTATION; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOPHENOTYPING; INFECTION; NEUTROPENIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SURVIVAL RATE;

EID: 3042837388     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(04)01512-8     Document Type: Note

References (75)

1. Schiffer CA. Hematopoietic growth factors and the future of therapeutic research on acute myeloid leukemia N Engl J Med 349 2003 727-729
2. Estey EH. Prognostic factors in acute myeloid leukemia Leukemia 15 2001 670-672
3. Kern W. Haferlach T. Schoch C. et al. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial Blood 101 2003 64-70
4. Wheatley K. Burnett AK. Goldstone AH. et al. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial Br J Haematol 107 1999 69-79
5. Lowemberg B. Prognostic factors in acute myeloid leukemia Best Pract Res Clin Haematol 14 2001 65-75
6. Mrozek K. Heinonen K. de la Chapelle A. Bloomfield CD. Clinical significance of cytogenetics in acute myeloid leukemia Semin Oncol 24 1997 17-31
7. Grimwade D. Walker H. Oliver F. et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial Blood 92 1998 2322-2333
8. Slovak ML. Kopecky KJ. Cassileth PA. et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study Blood 96 2000 4075-4083
9. Kohlmann A. Schoch C. Schnittger S. et al. Molecular characterization of acute leukemias by use of microarray technology Genes Chromosomes Cancer 37 2003 396-405
10. Giles FJ. Keating A. Goldstone AH. et al. Acute myeloid leukemia Hematology (Am Soc Hematol Educ Program) 1 2002 73-110
11. Grimwade D. Lo Coco F. Acute promyelocytic leukemia: a model for the role of molecular diagnosis and residual disease monitoring in directing treatment approach in acute myeloid leukemia Leukemia 16 2002 1959-1973
12. Tallman M. Nabhan C. Management of acute promyelocytic leukemia Curr Oncol Rep 4 2002 381-389
13. Appelbaum FR. Rowe JM. Radich J. Dick JE. Acute myeloid leukemia Hematology (Am Soc Hematol Educ Program) 1 2001 62-86
14. Wiernik PH. Banks PLC. Case DC Jr. et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia Blood 79 1992 313-319
15. Berman E. Heller G. Santorsa J. et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia Blood 77 1991 1666-1674
16. Vogler WR. Velez-Garcia E. Weinter RS. et al. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group study J Clin Oncol 10 1992 1103-1111
17. Berman E. Wiernik P. Vogler R. et al. Long-term follow-up of three randomized trials comparing idarubicin and daunorubicin as induction therapies for patients with untreated acute myeloid leukemia Cancer 80 suppl 11 1997 2181-2185
18. The AML Collaborative Group. A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. Br J Haematol 1998; 103: 100-09.
19. Vignetti M, de Witte T, Suciu S, et al. Daunorubicin (DNR) vs Mitoxantrone (MTZ) vs Idarubicin (IDA) administered during induction and consolidation in acute myeloid leukemia(AML) followed by autologous or allogeneic stem cell transplantation (SCT): results of the EORTC-GIMEMA. Blood 2003; 102: 175 (abstr).
20. Rowe JM, Neuberg D, Friedenberg W, A phase III study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood 2003; 102: 479-485.
21. Bishop JF. Matthews JP. Young GAR. et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia Blood 87 1996 1710-1717
22. Weick JK. Kopecky KJ. Appelbaum FR. et al. A randomized investigation of high dose versus standard dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia Blood 88 1996 2841-2851
23. Kern W, Estey E. High dose cytosine arabinoside in induction treatment of acute myeloid leukemia: meta-analysis of three trials involving 1691 randomized patients. Blood 2002; 100: 155 (abstr).
24. Bishop JF. Approaches to induction therapy with adult acute myeloid leukaemia Acta Haematol 99 1998 133-137
25. Hann IM. Stevens RF. Goldstone AH. et al. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia: results of the Medical Research Council's 10th AML trial (MRC AML10) Blood 89 1997 2311-2318
26. Ferrara F. Palmieri S. Pocali B. et al. De novo acute myeloid leukemia with multilineage dysplasia: treatment results and prognostic evaluation from a series of 44 patients treated with fludarabine, cytarabine and G-CSF (FLAG) Eur J Haematol 68 2002 203-209
27. Russo D. Pricolo G. Michieli M. et al. Fludarabine, arabinosyl cytosine and idarubicin (FLAI) for remission induction in poor-risk acute myeloid leukemia Leuk Lymphoma 40 2001 335-343
28. Parker JE. Pagliuca A. Mijovic A. et al. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia Br J Haematol 99 1997 939-944
29. Estey EH. Thall PF. Cortes JE. et al. Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts Blood 98 2001 3575-3583
30. Stone RM. Berg DRT. George SL. et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukaemia N Engl J Med 332 1995 1671-1678
31. Löwenberg B. Suciu S. Archimbaud E. et al. Use of recombinant granulocyte-macrophage colony-stimulating factor during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML-11, a phase II randomized study of the Leukemia Cooperative Group of European Organization and Treatment of Cancer and Dutch Belgian Hemato-oncology Cooperative Group (HOVON) Blood 90 1997 2952-2961
32. Witz F. Sadoun A. Perrin MC. et al. A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients Blood 91 1998 2722-2730
33. Godwin JE. Kopecky KJ. Head DR. et al. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group trial (9031) Blood 91 1998 3607-3615
34. Heil G. Hoelzer D. Sanz MA. et al. A randomized, double-blind, placebo-controlled, phase II study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia Blood 90 1997 4710-4718
35. Lowenberg B. van Putte W. Theobald M. et al. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia N Engl J Med 349 2003 743-752
36. Ferrara F. Schiavone EM. Palmieri S. et al. Complete remission induced by G-CSF in a patient with acute myeloid leukemia with t(8;21)(q22;q22) Hematol J 4 2003 218-221
37. Ferrara F. Di Noto R. Viola A. et al. Complete remission in acute myeloid leukaemia with t(8;21) following treatment with G-CSF: flow cytometric analysis of in vivo and in vitro effects on cell maturation Br J Haematol 106 1999 520-523
38. Piccaluga PP, Martinelli G, Malagola M, et al. Complete remission in acute myeloid leukemia with granulocyte-colony stimulating factor without chemotherapy: report of cytogenetic remission of a t(9;11)(p22q23) positive AML patient and review of literature. Haematologica 2003; 88: ECR28.
39. Buchner T. Hiddemann W. Wormann B. et al. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group Blood 93 1999 4116-4124
40. Kell WJ. Burnett AK. Chopra R. et al. A feasibility study of simultanenous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia Blood 102 2003 4277-4283
41. Burnett AK. Treatment of acute myeloid leukaemia in younger patients Best Pract Res Clin Haematol 14 2001 95-118
42. Mayer RJ. Davis RB. Schiffer CA. et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia N Engl J Med 331 1994 896-903
43. Burnett AK. Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation?-an adult treater's view Br J Haematol 118 2002 357-364
44. Wheatley K. Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation?-a statistician's view Br J Haematol 118 2002 351-356
45. Zittoun RA. Mandelli F. Willemze R. et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia N Engl J Med 332 1995 217-223
46. Harousseau JL. Cahn JY. Pignon B. et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia Blood 90 1997 2978-2986
47. Burnett AK. Wheatley K. Goldstone AH. et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial Br J Haematol 118 2002 385-400
48. Cassileth PA. Harrington DP. Appelbaum FR. et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukaemia in first remission N Engl J Med 339 1998 1649-1656
49. Tallman MS. Rowlings PA. Milone G. et al. Effect of postremission chemotherapy before human leukocyte antigen-identical sibling transplantation for acute myelogenous leukemia in first complete remission Blood 96 2000 1254-1258
50. Linker CA. Autologous stem cell transplantation for acute myeloid leukemia Bone Marrow Transplant 31 2003 731-738
51. Gorin NC. Autologous stem cell transplantation for adult acute leukaemia Curr Opin Oncol 14 2002 152-159
52. Palmieri S. Sebastio L. Mele G. et al. High-dose cytarabine as consolidation treatment for patients with acute myeloid leukemia with t(8;21) Leuk Res 26 2002 539-543
53. Ferrara F. Annunziata M. Schiavone EM. et al. High-dose idarubicin and busulphan as conditioning for autologous stem cell transplantation in acute myeloid leukemia: a feasibility study Hematol J 2 2001 214-219
54. Stein AS. O'Donnell MR. Slovak ML. et al. Interleukin-2 after autologous stem-cell transplantation for adult patients with acute myeloid leukemia in first complete remission J Clin Oncol 21 2003 615-623
55. Ferrara F. Del Vecchio L. Acute myeloid leukemia with t(8;21)/AML1/ETO: a distinct biological and clinical entity Haematologica 87 2002 306-319
56. Schnittger S. Weisser M. Schoch C. et al. New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcripts Blood 102 2003 2746-2755
57. Nguyen S. Leblanc T. Fenaux P. et al. A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup Blood 99 2002 3517-3523
58. Suciu S. Mandelli F. de Witte T. et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMA AML-10 trial Blood 102 2003 1232-1240
59. Kottaridis PD. Gale RE. Linch DC. Flt3 mutations and leukaemia Br J Haematol 122 2003 523-538
60. Stirewalt DL. Radich JP. The role of FLT3 in haematopoietic malignancies Nat Rev Cancer 3 2003 650-665
61. Ogawa H. Tamaki H. Ikegame K. et al. The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia Blood 101 2003 1698-1704
62. Burnett AK, Wheatley K, Stevens R, et al. Further data to question the use of allogeneic bone marrow transplant AML in 1st remission in addition to intensive chemotherapy: the MRC experience in 715 patients under age 44 years with donors available. Blood 2002; 100: 74 (abstr).
63. Chalandon Y. Barnett MJ. Horsman DE. et al. Influence of cytogenetic abnormalities on outcome after allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission Biol Blood Marrow Transplant 8 2002 435-443
64. Aversa F, Tabilio A, Velardi A, et al. Full haplotype mismatched transplant in high risk acute leukemia patients. Blood 2001; 98: 669 (abstr).
65. Ries LAG, Eisner MP, Kosary CL, eds. SEER cancer statistics review, 1973-1998. Bethesda, MD: National Cancer Institute, 2001.
66. Pinto A. Zagonel V. Ferrara F. Acute myeloid leukaemia in the elderly: biology and therapeutic strategies Crit Rev Oncol Hematol 39 2001 275-287
67. Ferrara F. Mirto S. Zagonel V. Pinto A. Acute myeloid leukemia in the elderly: a critical review of therapeutic approaches and appraisal of results of therapy Leuk Lymphoma 29 1998 375-382
68. Estey EH. How I treat older patients with AML Blood 96 2000 1670-1673
69. Gorin NC. Labopin M. Pichard P. et al. Feasibility and recent improvement of autologous stem cell transplantation for acute myelocytic leukaemia in patients over 60 years of age: importance of the source of stem cells Br J Haematol 110 2000 887-893
70. Ferrara F. Venditti A. Carella AM Jr. et al. Autologous stem-cell transplantation for patients with acute myeloid leukaemia aged over 60 yr Eur J Haematol 69 2002 200-204
71. Massenkeil G. Nagy M. Lawang M. et al. Reduced intensity conditioning and prophylactic DLI can cure patients with high-risk acute leukaemias if complete donor chimerism can be achieved Bone Marrow Transplant 31 2003 339-345
72. Wong R. Giralt SA. Martin T. et al. Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years Blood 102 2003 3052-3059
73. Taussig DC. Davies AJ. Cavenagh JD. et al. Durable remissions of myelodysplastic syndrome and acute myeloid leukemia after reduced-intensity allografting J Clin Oncol 15 2003 3060-3065
74. Ferrara F. Morabito F. Latagliata R. et al. Aggressive salvage treatment is not appropriate for the majority of elderly patients with acute myeloid leukaemia relapsing after first complete remission Haematologica 86 2001 814-820
75. Watson M. Zittoun R. Hall E. et al. A modular questionnaire for the assessment of long term quality of life in leukaemia patients: the MRC/EORTC QLQ-LEU Qual Life Res 5 1996 15-19